DDR inhibitors are primarily used in cancer therapy due to their ability to target DNA damage response pathways. By inhibiting these pathways, they prevent cancer cells from repairing DNA damage, leading to cell death. This makes them particularly effective in treating cancers with defective DNA repair mechanisms, such as certain types of breast, ovarian, and prostate cancers. Additionally, DDR inhibitors are often used in combination with other treatments like chemotherapy or radiation to enhance their efficacy. Their role in sensitizing tumor cells to DNA-damaging agents has shown promising results in improving patient outcomes. Ongoing research is exploring their potential in treating other diseases where DNA repair processes are dysregulated.